Medicare drug coverage faces an ominous spending outlook
There are troubling new signs that the overhaul of Medicare drug coverage in the Inflation Reduction Act is dramatically driving up program spending. Why it matters: The upward trajectory could threaten some seniors' coverage for outpatient prescription drugs — and it could force painful tradeoffs over the next decade as Medicare consumes a growing share of the nation's debt. Follow the money:…
Recent developments indicate Medicare drug coverage under the Inflation Reduction Act is escalating spending at an alarming rate, posing significant challenges for seniors' outpatient prescription drug coverage and potentially necessitating tough tradeoffs over the coming decade. The Inflation Reduction Act limited out-of-pocket costs for seniors' prescription drugs, shifting the remaining expense to taxpayers, private Medicare drug plans, and drug manufacturers.
This policy proved beneficial for patients with expensive medications, yet federal records reveal drug demand is surging as prices drop, outpacing initial spending projections.
According to Medicare advisers, more than 20% of beneficiaries reached the $2,000 patient cost cap in 2025, transferring additional expenses to the government. Catastrophic phase drug spending, where patients shoulder no out-of-pocket costs, made up 66% of the total drug program expenditure. Usage of GLP-1 weight-loss drugs contributed to this surge, as enrollees reached the cost cap for these medications earlier than in 2024.
Program spending more than tripled between 2024 and 2025, with larger increases in cancer and diabetes treatments. Despite the Inflation Reduction Act offering plans incentives to curb spending, limited tools are available. American Enterprise Institute senior fellow Benedic Ippolito emphasized the need for adjustments that preserve financial safeguards for enrollees while allowing more cost containment.
Anticipated Medicare spending, as projected by the Congressional Budget Office, is expected to surpass the economy's growth rate. By 2035, spending is estimated to reach $346 billion. The expiration of certain provisions and the upcoming end of the Biden administration's insurance premium stabilization program will likely increase costs for seniors in 2026.
Policy experts suggest potential reforms, such as implementing copays for expensive drugs, adjusting the patient cost cap, or permitting Medicare plans to gradually raise premiums. Ultimately, policymakers must grapple with fundamental questions about the level of funding for Medicare drugs.
Written by urgent.news from Axios's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
